VRXA
VRXA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$10K
Insider Sales
0
$0
Total Volume
$10K
1 transactions
Net Activity
+$10K
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Hosseinion Warren
Dir
$10K total
Quick Actions
VRXA has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at VRXA (VRXA) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $10K.
The net insider activity for VRXA shows a net buying bias of $10K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Hosseinion Warren (Dir), who traded 6.0K shares valued at $10K on Sep 10, 2026.
Veraxa Biotech AG (VRXA) Stock Price, News, Quote & History
symbol__ Stock Quote Price and Forecast
VRXA - Veraxa Biotech AG Stock Price and Quote
VRXA Stock Price and Chart — NASDAQ:VRXA
After BDO announced its resignation as auditor, Veraxa Biotech (VRXA) called a vote to elect KPMG.
VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
FAQs About VRXA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for VRXA.